Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Interim Management Statement

17 Oct 2013 14:39

RNS Number : 7890Q
Maven Income and Growth VCT 3 PLC
17 October 2013
 

 

Maven Income and Growth VCT 3 PLC (the Company)

 

Interim Management Statement - quarter ended 31 August 2013

 

This Interim Management Statement, for the quarter ended 31 August 2013, is provided in accordance with Rule 4.3 of the Disclosure and Transparency Rules of the UK Listing Authority and also includes relevant information in respect of the period from 1 September 2013 to the date of issue. This Statement has been prepared solely to provide additional information in order to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.

 

1.

Financial highlights

 

· Net asset value (NAV)1 of 80.95p per share at 31 August 2013, after payment of the interim dividend, compared to 82.60p per share at 31 May 2013;

· NAV total return2 of 117.40p at 31 August 2013, compared to 117.05p at 31 May 2013; and

· Interim dividend of 2.00p per share in respect of the year ending 30 November 2013, paid on 30 August 2013.

 

1The NAV is unaudited and reflects the closing bid price of quoted securities at 31 August 2013. Unlisted companies are normally valued on a six-monthly basis and the NAV incorporates the Directors' valuation of unlisted investments as at 31 May 2013, adjusted for subsequent events where appropriate.

2NAV total return is the sum of NAV per share and dividends paid per share since launch.

 

2.

Investments and disposals

 

During the quarter ended 31 August 2013, six new and four follow-on investments totalling a net amount of £3,635,284 were made in unlisted companies. In the same period, disposals from three unlisted company investments generated aggregate proceeds of £375,726 against a cost of £508,491; disposals of four AIM quoted investments generated aggregate proceeds of £173,247 against a cost of £269,513; and proceeds of £1,249,942 were realised from the sale of UK Government Securities.

 

3.

Recent developments

 

Between 1 September 2013 and the date of this Statement, two follow-on investments in unlisted companies totalling £86,952 were made and the disposal of an AIM quoted investment generated proceeds of £37,181 against a cost of £33,804. There was also a return of capital of £360,000 from an unlisted company investment.

 

Other than as described above, and changes in the value of investments quoted on regulated markets, the Board is not aware of any material events during the period from 1 June 2013 to 31 August 2013, or in the period from 1 September 2013 to the date of this announcement, which would have had a material impact on the financial position of the Company.

 

Issued on behalf of the Board

 

Maven Capital Partners UK LLP

Secretary

 

17 October 2013

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSFMMMGFNNGFZM
Date   Source Headline
20th May 202610:00 amRNSAdmission of Further Securities to Trading
15th May 202610:05 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:35 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20267:00 amRNSTransaction in Own Shares
30th Apr 20261:30 pmRNSResult of AGM
30th Apr 202610:54 amRNSAdmission of Further Securities to Trading
29th Apr 202612:28 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:19 amRNSAdmission of Further Securities to Trading
14th Apr 202611:07 amRNSIssue of Equity
8th Apr 20269:28 amRNSAdmission of Further Securities to Trading
25th Mar 202610:54 amRNSAdmission of Further Securities to Trading
24th Mar 20265:32 pmRNSAnnual Financial Report
24th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSNet Asset Value(s)
27th Feb 20265:01 pmRNSTransaction in Own Shares
27th Feb 20267:00 amRNSUnaudited NAV and Dividend Declaration
18th Feb 20264:52 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:05 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:00 amRNSDirector/PDMR Shareholding
17th Feb 202610:55 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:03 amRNSAdmission of Further Securities to Trading
16th Jan 20269:42 amRNSIssue of Equity
14th Jan 20262:35 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202510:20 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20254:47 pmRNSResult of General Meeting
28th Oct 20254:24 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:08 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:13 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:30 pmRNSHalf-year Report
22nd Jul 20254:49 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:46 pmRNSStatement re Unaudited NAV and Interim Dividend
15th May 20253:57 pmRNSTransaction in Own Shares
9th May 20259:54 amRNSDirector/PDMR Shareholding
9th May 20259:51 amRNSIssue of Equity
6th May 202511:53 amRNSIssue of Equity
2nd May 20251:11 pmRNSAudited NAV - Dividend Investment Scheme
1st May 20253:15 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:17 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.